PMID- 35387237
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2515-8414 (Electronic)
IS  - 2515-8414 (Linking)
VI  - 14
DP  - 2022 Jan-Dec
TI  - Optical coherence tomography patterns of diabetic macular edema and treatment 
      response to bevacizumab: a short-term study.
PG  - 25158414221074519
LID - 10.1177/25158414221074519 [doi]
LID - 25158414221074519
AB  - BACKGROUND: The purpose of this study was to evaluate the short-term response of 
      intravitreal bevacizumab in diabetic macular edema (DME) and assess the variation 
      in treatment outcomes in different morphology patterns using spectral 
      domain-optical coherence tomography (SD-OCT). OBJECTIVE: To study different 
      morphological patterns of DME based on OCT and compare their treatment response 
      to bevacizumab. METHODS: Hundred and twelve eyes of 112 patients with DME were 
      included and treated with intravitreal bevacizumab (1.25 mg/0.05 ml monthly for 
      3 months). The morphological patterns of DME were classified on the basis of OCT 
      into three groups - diffuse retinal thickening (DRT), cystoid macular edema 
      (CME), and serous retinal detachment (SRD) - and changes in central macular 
      thickness (CMT) and best corrected visual acuity (BCVA) after treatment were 
      compared. RESULTS: A total of 112 eyes with DME were included and consisted of 40 
      DRT, 37 CME, and 35 SRD. Treatment with bevacizumab resulted in decrease in 
      central macular thickness and improvement in BCVA in all three groups. The 
      baseline visual acuity and CMT of DRT group was better than that of the other two 
      groups. The treatment outcome was measured in terms of CMT and BCVA. Change in 
      CMT was statistically significant among three groups and was found to be better 
      in DRT group (p < 0.05, 95% confidence interval). However, there was 
      statistically no significant variation between the three groups regarding the 
      change in BCVA (p = 0.169, 95% confidence interval). CONCLUSION: Anatomic and 
      visual improvement can be achieved by bevacizumab in all patterns of DME. 
      However, individual pattern may respond differently. DRT, which appears to be the 
      earliest form of DME, responds better than other types. Thus, the pattern of 
      macular edema shown by OCT may provide an objective guideline in predicting the 
      response of bevacizumab injection in DME.
CI  - (c) The Author(s), 2022.
FAU - Sharma, Sadhana
AU  - Sharma S
AUID- ORCID: 0000-0002-0550-6938
AD  - Ophthalmologist, Mechi Eye Hospital, Jhapa 57200, Nepal.
FAU - Karki, Pratap
AU  - Karki P
AD  - Department of Retina, B.P. Koirala Lions Center for Ophthalmic Studies (BPKLCOS), 
      Institute of Medicine, Kathmandu, Nepal.
FAU - Joshi, Sagun Narayan
AU  - Joshi SN
AD  - Department of Retina, B.P. Koirala Lions Center for Ophthalmic Studies (BPKLCOS), 
      Institute of Medicine, Kathmandu, Nepal.
FAU - Parajuli, Sanket
AU  - Parajuli S
AD  - Reiyukai Eiko Masunaga Eye Hospital, Banepa, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20220331
PL  - United States
TA  - Ther Adv Ophthalmol
JT  - Therapeutic advances in ophthalmology
JID - 101728805
PMC - PMC8977703
OTO - NOTNLM
OT  - OCT
OT  - bevacizumab
OT  - diabetic macular edema
COIS- Conflict of interest statement: The authors declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2022/04/08 06:00
MHDA- 2022/04/08 06:01
PMCR- 2022/03/31
CRDT- 2022/04/07 05:22
PHST- 2021/06/30 00:00 [received]
PHST- 2022/01/03 00:00 [accepted]
PHST- 2022/04/07 05:22 [entrez]
PHST- 2022/04/08 06:00 [pubmed]
PHST- 2022/04/08 06:01 [medline]
PHST- 2022/03/31 00:00 [pmc-release]
AID - 10.1177_25158414221074519 [pii]
AID - 10.1177/25158414221074519 [doi]
PST - epublish
SO  - Ther Adv Ophthalmol. 2022 Mar 31;14:25158414221074519. doi: 
      10.1177/25158414221074519. eCollection 2022 Jan-Dec.